Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för roxadustat. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

11 träffar

Bibliografisk träff 2016-09-01

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.

Groenendaal-van de Meent D, Adel MD, Noukens J, Rijnders S, Krebs-Brown A, Mateva L, Alexiev A, Schaddelee M.

Clin Drug Investig · research-article; journal article · DOI 10.1007/s40261-016-0422-y

Bibliografisk träff 2016-04-19

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.

Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KP, Neff TB.

Clin J Am Soc Nephrol · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.2215/cjn.06890615

Bibliografisk träff 2016-04-18

Comparative systems pharmacology of HIF stabilization in the prevention of retinopathy of prematurity.

Hoppe G, Yoon S, Gopalan B, Savage AR, Brown R, Case K, Vasanji A, Chan ER, Silver RB, Sears JE.

Proc Natl Acad Sci U S A · comparative study; research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1073/pnas.1523005113

Bibliografisk träff 2016-04-01

Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1α and Increases Mitophagy to Reduce Cell Death After Experimental Retinal Detachment.

Liu H, Zhu H, Li T, Zhang P, Wang N, Sun X.

Invest Ophthalmol Vis Sci · research support, non-u.s. gov't; journal article · DOI 10.1167/iovs.15-18066

Bibliografisk träff 2016-03-29

Hypoxia enhances tenocyte differentiation of adipose-derived mesenchymal stem cells by inducing hypoxia-inducible factor-1α in a co-culture system.

Yu Y, Zhou Y, Cheng T, Lu X, Yu K, Zhou Y, Hong J, Chen Y.

Cell Prolif · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cpr.12250

Bibliografisk träff 2016-03-04

The Hypoxia-inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat (FG-4592) and Warfarin in Healthy Volunteers: A Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction Study.

Groenendaal-van de Meent D, den Adel M, Rijnders S, Krebs-Brown A, Kerbusch V, Golor G, Schaddelee M.

Clin Ther · clinical trial, phase i; journal article · DOI 10.1016/j.clinthera.2016.02.010

Bibliografisk träff 2016-02-02

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB.

Am J Kidney Dis · clinical trial, phase ii; comparative study; multicenter study; randomized controlled trial; journal article · DOI 10.1053/j.ajkd.2015.12.020

Bibliografisk träff 2016-01-15

Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case.

Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A.

J Pharm Biomed Anal · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jpba.2016.01.029

Bibliografisk träff 2015-12-17

Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.

Wu K, Zhou K, Wang Y, Zhou Y, Tian N, Wu Y, Chen D, Zhang D, Wang X, Xu H, Zhang X.

Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.brainres.2015.12.017

Bibliografisk träff 2015-10-22

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.

Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB.

J Am Soc Nephrol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1681/asn.2015030241

Bibliografisk träff 2015-08-03

Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.

Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB.

Nephrol Dial Transplant · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1093/ndt/gfv302